TX-MARY-KAY
8.6.2023 18:03:31 CEST | Business Wire | Press release
Mary Kay is celebrating Ocean’s Week by reaffirming its decades-long partnership with The Nature Conservancy (TNC) to support ocean conservation and coral reef protection. Coral reefs, often referred to as the rainforests of the sea, cover less than 1% of the world’s surface area but support 25% of all marine life and over one billion people.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005582/en/
Dr. Elizabeth McLeod, The Nature Conservancy’s Global Oceans Director, conducting research in Ulong Channel, Palau as part of the Super Reefs project, a collaborative effort to discover the secrets of “super reefs” with support from Mary Kay. (Credit: © Kip Evans/CCC Marketing)
Because traditional reef conservation strategies have not been enough to counter the global loss of coral reefs, Mary Kay, a signatory to the UN Global Compact Sustainable Ocean Principles, is supporting experts from TNC, Woods Hole Oceanographic Institution (WHOI), and Stanford University as they lead a collaborative effort to discover the secrets of “super reefs” – a diverse coral community within a reef system that is more resistant or resilient to damaging heatwaves – in efforts to predict, prove, and protect critical coral reefs.
Mary Kay’s continued support of TNC’s Global Oceans and Super Reefs programs allows researchers to assess reef health, identify potential super reef locations, and discuss opportunities to improve reef management locally. This information will help guide conservation and restoration efforts. Current areas of interest for super reefs work include Hawaii, Palau, Indonesia, the Marshall Islands, the Bahamas, the Dominican Republic, and Belize.
“Like all rivers and tributaries, most good things in our world lead back to oceans,” said Deborah Gibbins, Chief Operations Officer at Mary Kay Inc. “Mary Kay is working with partners like The Nature Conservancy to protect Earth’s most valuable resources. Clean, healthy water isn’t just essential to our business—it’s essential for life everywhere.”
“TNC is committed to conserving 4 billion hectares of the ocean by 2030, and we are grateful for support from Mary Kay to help achieve this critical goal. Strong partnerships with governments, non-profits, companies, and local communities are essential to our success,” said Dr. Lizzie Mcleod, TNC’s Global Oceans Director.
This year, Mary Kay will also continue its support of the Coastal Wetlands in Texas, the beauty brand’s home state. In 2023, TNC will continue working toward its three-year project objectives:
- identify priority wetland areas for protection and restoration across more than 27,000 kilometers of shoreline along the Gulf of Mexico,
- produce a Coastal Conservation and Restoration Action Plan for Texas’ three blue carbon ecosystems—mangroves, salt marsh, and seagrass—including mapping areas where we expect wetlands will migrate in the future due to climate change,
- assess the feasibility of blue carbon markets to support long-term wetland management needs in Texas, and
- identify a dynamic coastal wetland site that can be established as a “living laboratory” to share conservation techniques, explore blue carbon offsets, and highlight the importance of these critical ecosystems.
In 1990, Mary Kay and TNC announced their partnership. Mary Kay’s conservation efforts started off close to home, focusing on protecting and preserving the natural resources of Texas. Over the last 33 years, Mary Kay’s support has grown to hundreds of projects in partnership with TNC including ocean work and coral reef restoration around the globe. Through its partnership with TNC, Mary Kay has also elevated women’s leadership in marine conservation to sustain programs that build gender equity into conservation efforts.
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 76 countries and territories—37 by direct conservation impact and 39 through partners—we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
